Source comparison
MK-677 Half Life: Dosing Window Comparison
Once-Daily (25mg) High (CV <20% at steady state) Maximal sustained elevation Low. Single daily administration Long-term growth studies, IGF-1 elevation protocols Alternate-Day (25mg) Moderate (50% trough on off-days) 60–70% of daily dosing AUC Low. Every 48 ho
This comparison does not assign a generated winner or score.
- Once-Daily (25mg)
- High (CV <20% at steady state)
- Maximal sustained elevation
- Low. Single daily administration
- Long-term growth studies, IGF-1 elevation protocols
- Alternate-Day (25mg)
- Moderate (50% trough on off-days)
- 60–70% of daily dosing AUC
- Low. Every 48 hours
- Intermittent exposure models, cost reduction
- Cycling (5 weeks on / 2 off)
- High during on-cycle, zero during washout
- Equivalent to daily during active phase
- Moderate. Calendar tracking required
- Receptor sensitivity studies, feedback loop investigation
- Split Dosing (12.5mg BID)
- Very high (minimal trough variation)
- Equivalent to once-daily total dose
- High. Twice-daily administration
- Not typically used; 24-hour half life makes splitting unnecessary